Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K + channel activation by NS1643

Molecular Pharmacology

Volumn 79, Issue 1, 2011, Pages 1-9

  Grunnet, Morten ^a,b   Abbruzzese, Jennifer ^c,d   Sachse, Frank B ^c,e   Sanguinetti, Michael C ^c,d  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Department of Electrical and Computer Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(2 HYDROXY 5 TRIFLUOROMETHYLPHENYL)UREA; MUTANT PROTEIN; NS 1643; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SENSITIVITY; MOLECULAR MODEL; MUTAGENESIS; NONHUMAN; OOCYTE; POINT MUTATION; PRIORITY JOURNAL; XENOPUS LAEVIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BINDING SITES; CRESOLS; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HUMANS; MODELS, MOLECULAR; PHENYLUREA COMPOUNDS; POINT MUTATION; UP-REGULATION; XENOPUS LAEVIS;

EID: 78651327258     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.067728     Document Type: Article

References (34)

1. Casis O, Olesen SP, and Sanguinetti MC (2006) Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 69:658-665.
2. Chen J, Zou A, Splawski I, Keating MT, and Sanguinetti MC (1999) Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation. J Biol Chem 274:10113-10118.
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, and Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
4. Diness JG, Hansen RS, Nissen JD, Jespersen T, and Grunnet M (2009) Antiarrhythmic effect of IKr activation in a cellular model of LQT3. Heart Rhythm 6:100-106.
5. Diness TG, Yeh YH, Qi XY, Chartier D, Tsuji Y, Hansen RS, Olesen SP, Grunnet M, and Nattel S (2008) Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc Res 79:61-69.
6. Gerlach AC, Stoehr SJ, and Castle NA (2010) Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Mol Pharmacol 77:58-68.
7. Gordon E, Lozinskaya IM, Lin Z, Semus SF, Blaney FE, Willette RN, and Xu X (2008) 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Mol Pharmacol 73:639-651.
8. Grunnet M, Diness TG, Hansen RS, and Olesen SP (2008) Biophysical characterization of the short QT mutation hERG-N588K reveals a mixed gain-and loss-offunction. Cell Physiol Biochem 22:611-624.
9. Hansen RS, Diness TG, Christ T, Demnitz J, Ravens U, Olesen SP, and Grunnet M (2006a) Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Mol Pharmacol 69:266-277.
10. Hansen RS, Diness TG, Christ T, Wettwer E, Ravens U, Olesen SP, and Grunnet M (2006b) Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5- yl)-phenyl)-N′-(3′- trifluoromethylphenyl)urea]. Mol Pharmacol 70:1319-1329.
11. Hansen RS, Olesen SP, and Grunnet M (2007) Pharmacological activation of rapid delayed rectifier potassium current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart. J Pharmacol Exp Ther 321:996-1002.
12. Hansen RS, Olesen SP, Rønn LC, and Grunnet M (2008) In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig. J Cardiovasc Pharmacol 52:35-41.
13. Hondeghem LM (2008) Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur J Pharmacol 584:1-9.
14. + channel. Mol Pharmacol 67:827-836.
15. Larsen AP, Olesen SP, Grunnet M, and Jespersen T (2008) Characterization of hERG1a and hERG1b potassium channels-a possible role for hERG1b in the I (Kr) current. Pflugers Arch 456:1137-1148.
16. Larsen AP, Olesen SP, Grunnet M, and Poelzing S (2010) Pharmacological activation of IKr impairs conduction in guinea pig hearts. J Cardiovasc Electrophysiol 21:923-929.
17. + channel in mouse and human hearts. Circ Res 81:719-726.
18. + current. Circ Res 81:870-878.
19. Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, Pugsley M, and Gallacher DJ (2008) Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol 154:1427-1438.
20. Morais Cabral JH, Lee A, Cohen SL, Chait BT, Li M, and Mackinnon R (1998) Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell 95:649-655.
21. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, and Lehmann MH (1995) ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 92:2929-2934.
22. + conductance. Proc Natl Acad Sci USA 106:20075-20080.
23. Perry M, Sachse FB, and Sanguinetti MC (2007) Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc Natl Acad Sci USA 104:13827-13832.
24. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, et al. (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45.
25. Kr potassium channel. Cell 81:299-307.
26. Sanguinetti MC and Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26:119-124.
27. Sanguinetti MC and Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia. Nature 440:463-469.
28. Su Z, Limberis J, Souers A, Kym P, Mikhail A, Houseman K, Diaz G, Liu X, Martin RL, Cox BF, et al. (2009) Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol 77:1383-1390.
29. Trudeau MC, Warmke JW, Ganetzky B, and Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269:92-95.
30. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, and Veltri EP (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348:7-12.
31. Warmke JW and Ganetzky B (1994) A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 91:3438-3442.
32. Xu X, Recanatini M, Roberti M, and Tseng GN (2008) Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4- dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). Mol Pharmacol 73:1709-1721.
33. Zhang M, Korolkova YV, Liu J, Jiang M, Grishin EV, and Tseng GN (2003) BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys J 84:3022-3036.
34. Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, and Cordes JS (2005) Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 68:876-884.